What is Neuraxis?
Headquartered in Carmel, Indiana, Neuraxis is a growth-stage enterprise dedicated to pioneering neuromodulation therapies. The company's core mission revolves around developing innovative solutions to address chronic and debilitating conditions, with a particular focus on pediatric applications. Established in 2011, Neuraxis has been steadily advancing its technology pipeline, aiming to provide new therapeutic avenues for patient populations facing significant health challenges.
How much funding has Neuraxis raised?
Neuraxis has raised a total of $9.6M across 2 funding rounds:
Stock Offering
$6.6M
Stock Offering
$3M
Stock Issuance/Offering (2023): $6.6M, investors not publicly disclosed
Stock Issuance/Offering (2023): $3M, investors not publicly disclosed
What's next for Neuraxis?
The recent major strategic investment positions Neuraxis for accelerated growth and the potential expansion of its therapeutic offerings. This influx of capital is expected to fuel further research and development, potentially leading to expanded clinical trials and the scaling of manufacturing capabilities. The company's focus on a critical unmet need in pediatric chronic conditions suggests a strategic path toward market penetration and establishing itself as a leader in the neuromodulation space.
See full Neuraxis company page
